Development of a new device to measure arterial stiffness and its reliability, and its potential to detect history of cardiovascular events in patients with chronic kidney disease Authors: Yuki Takeda, Sawako Kato, Junfeng Wang, Masahiko Ando, Takeo Matsumoto, Yasuko Yoshida, Hiroshi Masuda, Shoichi Maruyama Published: 2026 ABSTRACT ABSTRACTAtherosclerosis, which leads to cardiovascular disease (CVD), can progress without any symptoms. To prevent CVD, it is important to detect atherosclerotic lesions early and assess their severity. Atherosclerosis evaluation for primary prevention is a preferable non-invasive diagnostic tool. In this study, a new device was developed to measure arterial stiffness. This new device measures the pressure–volume relationship during avascularization and the upper arm release process, similar to an automatic blood pressure monitor. The proportionality coefficient between pressure and volume was calculated from this curve; the larger the proportionality coefficient, the greater the arterial stiffness. Using this device, the arterial stiffness index (ASI), standard arteriosclerosis indices, cardio-ankle vascular index (CAVI), ankle-brachial pressure index (ABI), and pulse wave velocity (PWV) were measured in 97 patients with chronic kidney disease and investigated the associations between ASI and these arteriosclerosis indices, as well as CVD history. A positive correlation was observed between ASI and PWV (P = 0.04); however, ABI and CAVI showed no correlation with ASI when analyzed using multiple regression, adjusting for age, sex, smoking, diastolic pressure, and serum creatinine. Furthermore, ASI was related to CVD history by an odds ratio of 1.03 (95% CI, 1.01–1.06) using logistic regression analysis adjusted for age, sex, smoking, and diastolic pressure, whereas CAVI, PWV, and ABI showed no relation to CVD history. ASI measured by our device is easier to measure than indices by devices in everyday use and was the only index to identify actual atherosclerotic disease events. INTRODUCTION Despite the decade-long decline in mortality because of cardiovascular disease (CVD), it remains a leading fatal disease worldwide.1 This decline in CVD mortality has been achieved through a combination of reductions in the prevalence of traditional CVD risk factors, particularly smoking, hypertension, dyslipidemia, diabetes, and obesity, as well as improvements in acute treatment and better secondary prevention.2 Intervention against traditional CVD risk factors prevent accelerate classical arteriosclerosis, and has successfully contributed to preventing arteriosclerosis, resulting in the reduction of fatal ischemic heart diseases and stroke.3 Since atherosclerosis now affects younger people and more women than previously reported, and risk factor profiles have changed,4 alterations in the etiology of atherosclerosis may affect its structure and characteristics into a new type of arteriosclerosis. Therefore, it is believed that it is necessary to detect a new type of arteriosclerosis to prevent CVD and to develop a new device to accurately evaluate arteriosclerosis. Currently, methods for evaluating arteriosclerosis include invasive diagnostic methods such as angiography and intravascular ultrasound; non-invasive morphological evaluation methods such as magnetic resonance imaging, magnetic resonance angiography, and multi-detector row computed tomography (CT); and vascular function tests such as ankle-brachial index (ABI),5 pulse wave velocity (PWV),6 cardio-ankle vascular index (CAVI),7 and flow-mediated vasodilation (FMD).8,9 It is important to combine these methods according to the case to accurately evaluate arteriosclerosis; however, the above devices are invasive or require special equipment and trained technicians. Therefore, it is currently not possible to measure arteriosclerosis on a daily basis.9 A new device that measures vascular wall elasticity noninvasively and as easily as a blood pressure monitor was developed. By adding technology to measure the vascular volume to the cuff used in blood pressure monitors, it is possible to obtain biological information on the characteristics of the wall tissue (vascular pressure–volume relationship) composed of smooth muscle, elastin, and collagen that make up the vascular wall. This study assumed a coefficient calculated by the vascular pressure–volume relationship curve to indicate an arterial stiffness index (ASI). This study was purposed to measure ASI using our device in patients with arteriosclerotic disease and patients suspected of having arteriosclerosis (patients with risk factors), and to compare ASI using our device with other representative arteriosclerosis indices. Additionally, the relationship between ASI using our device and the history of CVD was clarified. Although similar vascular pressure–volume relationships have been measured in healthy individuals in the past,10,11 there have been no reports of clinical measurements and examinations of these relationships in patients with arteriosclerosis. This study evaluated the ASI using a vascular pressure–volume relationship curve measured by our developed device to compare atherosclerotic markers currently in use and to explore the implications of ASI in clinical settings. Simple, easy, reliable, and accurate devices to evaluate new types of arteriosclerosis may be developed for use during health checkups, in addition to medical facilities, which may be useful for primary prevention of atherosclerosis and reduction of CVD incidence. MATERIALS AND METHODS Study participants and design The present study group comprised patients attending Nagoya University Hospital as outpatients in the Department of Nephrology from December 2020 to July 2022. Individuals with a history of atherosclerotic disease and/or associated risk factors were recruited. The study protocol (STudy of PrActical and Clinical Usefulness of Vascular Pressure–Volume Curve as a New ATherOsclerosis Marker: STACCATO study) was approved by the Ethics Committee of Nagoya University School of Medicine (no. 2020-0397) and was conducted in accordance with the guidelines of the Declaration of Helsinki. After being informed of the study’s purpose, written consent was obtained from all enrolled patients for their participation. Baseline demographic and clinical data, such as age, sex, current medications, and history of CVD, were collected from patient records. Lifestyle factors, including exercise, smoking, and drinking, were assessed during the interviews. Laboratory data were obtained using an automatic analyzer at the Clinical Laboratory of Nagoya University Hospital. Measurement of vascular pressure–volume curve Figure 1A shows the developed measurement device (LaView Corp, Japan), which consisted of a cuff, main body, and control tablet. A schematic diagram of the measurement setup is shown in Fig. 1B. The cuff was wrapped around the upper arm, and measurements were performed by inflating and deflating the cuff in a manner similar to conventional blood pressure measurements. The cuff pressure control protocol is illustrated in Fig. 1C. In phase (1), the cuff is rapidly inflated at ~100 mmHg/s to a pressure 50 mmHg higher than the subject’s premeasured systolic blood pressure, thereby occluding the brachial artery. In phase (2), inflation was halted, and the cuff volume was maintained for 30 seconds to stabilize the condition. In phase (3), the cuff was gradually deflated at ~10 mmHg/s until the pressure decreased to 18 mmHg. During this process, the brachial artery, previously collapsed by inflation, gradually reopened, and the mechanical properties of the artery were estimated from the pressure trajectory during this phase (Fig. 1D). In phase (4), deflation was stopped, and the cuff volume was maintained for 80 seconds, during which vascular dilation was estimated from the change in cuff pressure. Schema of arterial stiffness measurement with the device developed in the present study Fig. 1A: Overview of the device Fig. 1B: Setup for the measurement Fig. 1C: Time sequence of the cuff pressure. In phase (1), the cuff is rapidly inflated at ~100 mmHg/s to a pressure 50 mmHg higher than the subject’s premeasured systolic blood pressure, thereby occluding the brachial artery. In phase (2), inflation was halted, and the cuff volume was maintained for 30 seconds to stabilize the condition. In phase (3), the cuff was gradually deflated at ~10 mmHg/s until the pressure decreased to 18 mmHg. During this process, the brachial artery, previously collapsed by inflation, gradually reopened, and the mechanical properties of the artery were estimated from the pressure trajectory during this phase as shown in Fig. 1E. In phase (4), deflation was stopped, and the cuff volume was maintained for 80 seconds, during which vascular dilation was estimated from the change in cuff pressure. Fig. 1D: Measurement of arterial volume from the cuff pressure curves. In phase (3), air is vented from the cuff, thereby allowing the arm to expand. The cuff pressure decreases as indicated by the dark blue curve if no artery is present in the arm. When an artery is present, the vessel reopening increases the arm volume, which suppresses the pressure drop and produces the trajectory shown by the orange curve. The arterial volume can be estimated from the pressure difference between the measured orange curve and the reference curve. Fig. 1E: Pressure–volume curve obtained by plotting the transmural pressure on the vertical axis against the arterial volume on the horizontal axis. Figure 1D schematically illustrates the pressure change in phase (3). During deflation, air is vented from the cuff at a constant rate, thereby reducing the cuff volume and allowing the arm to expand. If no artery is present in the upper arm, the cuff pressure decreases, as indicated by the dark blue curve. In contrast, when an artery is present, the vessel reopening increases the arm volume, which suppresses the pressure drop and produces the trajectory shown by the orange curve. The no-artery reference curve shown in dark blue was extrapolated from the high-pressure region of the curve. The arterial volume can be estimated from the pressure difference between the measured orange curve and the reference curve. The arterial pressure–volume curve was obtained by plotting the transmural pressure (arterial pressure minus cuff pressure) on the vertical axis against the arterial volume on the horizontal axis (Fig. 1E). The slope of this curve reflects the arterial stiffness. The slope of the middle region was defined as the ASI. A higher ASI indicates stiffer arteries, whereas a lower ASI indicates more compliant arteries. During phase (3), progressive vessel reopening imposes high wall shear stress on the endothelial cells, eliciting an FMD response. This leads to arterial expansion in phase (4), which increases the arm volume. Because the cuff volume was kept constant during this phase, the cuff pressure increased. Using Boyle’s law, the volume increase can be calculated from this pressure increase, allowing for the quantification of vasodilation.12 ASI was measured at the point where the cuff pressure has decreased to the level corresponding to the diastolic blood pressure, at which the vessel is fully open and pulsatile. This point corresponds to the region of the pressure–volume curve where the slope is the shallowest. The reproducibility of ASI was assessed by comparing two consecutive measurements performed at 3-minute intervals. The difference between the two measurements was –7.3 ± 22.5% (mean ± SD, n = 72). Determination of PWV, CAVI, and ABI Measurements of CAVI and PWV were performed with the subjects in the supine position after 15 minutes of rest according to a standard protocol using a Colin waveform analyzer (Form PWV/ABI; Colin Medical Technology, Komaki, Japan; https://www.fukuda.co.jp/colin/products/basic/240.html), which simultaneously measures bilateral arm and ankle BP and pulse volumes of the brachial and posterior tibial arteries, respectively, using an oscillometric method. The ABI was calculated as the ratio of ankle systolic pressure to arm systolic pressure. Statistical analysis Continuous variables are shown as mean ± standard deviation and/or median and interquartile range (25th–75th percentiles). We divided the patients into two groups according to the median values of the arterial stiffness index (ASI) measured by our device: a high-ASI group and a low-ASI group. Comparisons between the two groups were assessed for continuous variables using Student’s unpaired t-test. The chi-square test was used for intergroup comparisons of categorical variables. Correlations among the indices of arteriosclerosis were assessed using multiple regression analysis, with adjustments made for age, sex, smoking status, serum creatinine level, and diastolic blood pressure. Relationships to a history of CVDs were assessed by logistic regression analysis adjusted for age, sex, and smoking status. Statistical significance was set at P < 0.05. All statistical analyses were performed using JMP statistical software (version Pro17; SAS Institute, Inc, Cary, NC, USA). RESULTS Characteristics and laboratory biomarkers Ninety-seven subjects were studied. The mean ± standard deviation of ASI measured by our device was 68.9 ± 21.4. The median (interquartile range) was 65.3 (53.1–81.0). The participants were divided into high- and low-ASI groups based on their median ASI. Clinical characteristics and laboratory biomarkers are reported in Tables 1 and 2, respectively. There were no significant differences in age, sex, body mass index, drinking habits, medications for diabetes, hypertension, or hyperlipidemia between the two groups; however, the proportion of current smokers was greater in the high-ASI group. Higher systolic blood pressure and lower diastolic blood pressure were observed in the high-ASI group compared to the low-ASI group, resulting in much more dilation in pulse pressure, which is logically compatible. Patients with high ASI had significantly more advanced renal dysfunction. Because patients who regularly visited the outpatient clinic of the nephrology department were recruited, all enrolled patients had some form of chronic kidney disease (CKD). There was no significant difference in the levels of leukocytes, hemoglobin, albumin, total cholesterol, and inflammation markers between the two groups; however, patients in the high-ASI group showed advanced renal dysfunction. Table 1 Characteristics of the study participantsTotalHigh arterial stiffness index (>65.3 mmHg)Low arterial stiffness index (<65.3 mmHg)P valueNumber974849Age, year65.6 ± 13.366.1 ± 13.365.2 ± 13.5NSMale (%)61 (62.9)31 (64.6)30 (61.2)NSSmoking (%)0.019* Current5 (5.1)5 (10.4)0 (0.0) Ex-smokers41 (42.3)21 (43.7)20 (40.8)Alcohol (%)NS Regular25 (25.8)13 (27.1)12 (24.5) Occasional17 (17.5)8 (16.7)9 (18.4)Exercise (%)NS Regular30 (30.1)17 (35.4)13 (26.5) Sometimes19 (19.6)10 (20.8)9 (18.4)Medication Diabetes (%)46 (47.4)27 (56.3)19 (38.8)NS Hypertension (%)87 (89.7)44 (91.6)43 (87.8)NS Hyperlipidemia (%)71 (73.2)35 (72.9)36 (73.5)NSBMI, kg/m224.8 ± 4.424.4 ± 4.925.1 ± 3.9NSSBP, mmHg135.9 ± 17.7144.1 ± 16.8127.8 ± 14.6<.0001*DBP, mmHg74.1 ± 11.771.6 ± 11.976.5 ± 11.10.038*PP, mmHg61.7 ± 16.272.5 ± 14.251.2 ± 9.9<.0001*Data are presented as mean ± standard deviation unless otherwise noted. *P < 0.05.BMI: body mass indexSBP: systolic blood pressureDBP: diastolic blood pressurePP: pulse pressureNS: not significant Characteristics of the study participants Data are presented as mean ± standard deviation unless otherwise noted. *P < 0.05. BMI: body mass index SBP: systolic blood pressure DBP: diastolic blood pressure PP: pulse pressure NS: not significant Table 2 Laboratory biomarkersTotalHigh arterial stiffness index (>65.3 mmHg)Low arterial stiffness index(<65.3 mmHg)P valueLeukocyte count, mean (SD), /mm36645 (2424)6838 (2552)6457 (2302)NSHemoglobin, mean (SD), g/dL13.2 (1.9)13.3 (1.8)13.2 (2.0)NSAlbumin, mean (SD), g/dL4.05 (0.32)4.04 (0.36)4.07 (0.29)NSCreatinine, mean (SD), mg/dL1.66 (1.1)1.95 (1.3)1.37 (0.7)0.009*eGFR, mean (SD), mL/min/1.73 m242.2 (23.2)36.6 (20.2)47.7 (24.8)0.018*Total cholesterol a, mean (SD), mg/dL195.0 (38.6)201.2 (37.4)189.1 (39.1)NSCRP a, median (range), mg/dL0.06 (0.01–3.06)0.09 (0.01–0.99)0.06 (0.02–3.06)NSa n = 91, mean ± SD unless skewed, in which case median [IQR]. *P < 0.05.SD: standard deviationeGFR: estimated glomerular filtration rateCRP: C-reactive proteinNS: not significant Laboratory biomarkers a n = 91, mean ± SD unless skewed, in which case median [IQR]. *P < 0.05. SD: standard deviation eGFR: estimated glomerular filtration rate CRP: C-reactive protein NS: not significant Association among the arterial stiffness indices measured by our device and those now in use Table 3A and Figure 2 presents the mean ASIs and distributions used in this study, respectively. Figure 3 and Table 3A illustrates the association between the ASIs measured using our device and PWV, CAVI, and ABI. PWV is the speed at which a heartbeat runs through the arteries; the faster this speed, the more advanced the arteriosclerosis.6 This study found a positive correlation between the ASI and PWV. PWV is the most popular index, but it depends on blood pressure at the time of measurement.6 CAVI develops independently of blood pressure at the time of measurement and may reflect the proper change in the arterial wall.7 There was no correlation between the ASI and CAVI. ABI is commonly used for the non-invasive diagnosis of lower-extremity peripheral artery disease.13 The most commonly used ABI threshold is <0.90 to detect peripheral arterial disease, and individuals with a high ABI >1.40 are also at an increased risk of CVD.13 Patients were divided into three groups: high ABI (>1.40), normal (0.9≤ABI≤1.4), and low (<0.9). There was no correlation between ASI and ABI. In these three multiple regression models, the covariates of serum creatinine and diastolic blood pressure were significantly correlated to ASI (Table 3B). Table 3 Correlation of ASI with PWV, CAVI, and ABI A) ASI MeanSDASI by our device (mmHg)68.921.4PWV (cm/s)816.5130.1CAVI8.41.3ABI1.10.1 B) Association with ASI by our device Estimated valueStandard betaVIFP value PWV 0.040.231.480.0488* Age−0.25−0.161.46NS Sex, male4.180.191.65NS SmokingNS smoking, ex- vs never−9.25−0.261.79 smoking, current vs ex-−6.37−0.171.26 Creatinine5.750.301.130.004* DBP−0.56−0.311.100.002*Estimated valueStandard betaVIFP value CAVI 3.970.131.32NS Age−0.29−0.111.37NS Sex, male4.410.201.67NS Smoking0.045* smoking, ex- vs never4.110.101.66 smoking, current vs ex-24.520.251.15 Creatinine5.770.301.140.002* DBP−0.49−0.271.070.009*Estimated valueStandard betaVIFP value ABI NS ABI, normal vs low 8.620.071.06 ABI, high vs normal −15.28−0.071.03Age−0.06−0.031.19NSSex, male3.680.171.70NSSmoking0.016*smoking, ex- vs never4.280.101.67smoking, current vs ex-25.930.271.12Creatinine5.620.291.140.005* DBP−0.49−0.271.080.008*Correlations among the indices of arteriosclerosis were assessed using multiple regression analysis, with adjustments made for age, sex, smoking status, serum creatinine level, and diastolic blood pressure. *P < 0.05.ASI: arterial stiffness indexPWV: pulse wave velocityCAVI: cardio-ankle vascular IndexABI: ankle-brachial pressure indexVIF: variance inflation factorDBP: diastolic blood pressureSD: standard deviation Correlation of ASI with PWV, CAVI, and ABI Correlations among the indices of arteriosclerosis were assessed using multiple regression analysis, with adjustments made for age, sex, smoking status, serum creatinine level, and diastolic blood pressure. *P < 0.05. ASI: arterial stiffness index PWV: pulse wave velocity CAVI: cardio-ankle vascular Index ABI: ankle-brachial pressure index VIF: variance inflation factor DBP: diastolic blood pressure SD: standard deviation Distributions of ASI by our device, PWV, CAVI and ABI ASI: arterial stiffness index PWV: pulse wave velocity CAVI: cardio-ankle vascular index ABI: ankle-brachial pressure index Association of ASI by our device with (A) PWV, (B) CAVI and (C) ABI ASI: arterial stiffness index PWV: pulse wave velocity CAVI: cardio-ankle vascular index ABI: ankle-brachial pressure index Association between a history of CVDs and ASIs Patients with a history of CVDs are presumed to develop arteriosclerosis.1 Next, this study assessed the ability of these ASIs to detect a history of CVDs. Out of the enrolled patients, 32 had already experienced CVDs before study entry, including 14 myocardial infarctions, 5 heart failures that required hospitalization, 17 strokes, and 5 aortic diseases (some patients experienced multiple events). Table 4 shows the association between a history of CVDs and the ASIs. ASI was the only factor associated with a history of CVDs, whereas PWV, CAVI, and ABI were unrelated to them. Table 4 Association with history of cardiovascular events to ASIsOdds ratio95% CILowerUpperASI by our device (mmHg)1.021.0011.047PWV (cm/s)1.000.9981.006CAVI0.970.6971.354ABI1.41––Relationships with the history of cardiovascular events were assessed using logistic regression analysis adjusted for age, sex, smoking, and diastolic pressure. The 95% CI for ABI is shown as –, since most participants had normal ABI values, with very few in the abnormal range, leading to sparse data and unstable estimation in the regression model. *P < 0.05.ASI: arterial stiffness indexPWV: pulse wave velocityCAVI: cardio-ankle vascular indexABI: ankle-brachial pressure index Association with history of cardiovascular events to ASIs Relationships with the history of cardiovascular events were assessed using logistic regression analysis adjusted for age, sex, smoking, and diastolic pressure. The 95% CI for ABI is shown as –, since most participants had normal ABI values, with very few in the abnormal range, leading to sparse data and unstable estimation in the regression model. *P < 0.05. ASI: arterial stiffness index PWV: pulse wave velocity CAVI: cardio-ankle vascular index ABI: ankle-brachial pressure index DISCUSSION This study evaluated this device’s ability to detect atherosclerosis in ASIs. Importantly, ASI is a physical index that theoretically calculates elasticity based on the curve between the measured volume of a confined space and the pressure applied to it. The measured ASI indicated a parallel increase in pulse pressure and PWV and was associated with smoking, a representative atherosclerotic risk factor. Interestingly, only the ASI measured by this device was related to a history of CVD among the ASIs measured by common non-invasive methods. Although a dramatic decline in the incidence and mortality of CVD has been reported in Western countries through various interventions, CVD remains a serious and fatal disease worldwide.4 Since CVD was originally caused by atherosclerosis, the current focus is on addressing atherosclerosis in younger people and women, who have seen a relative increase in CVD.4 Recently, the concept of cardiovascular-kidney-metabolic (CKM) syndrome was released,14,15 that representing a decade of alteration in CVD risk. CKM health reflects the interplay among metabolic risk factors, CKD, and CVD, including heart failure, and has a profound impact on morbidity and mortality.14 Kidney dysfunction is increasingly recognized as a key mediator of the relationship between CVD, particularly heart failure, and metabolic risk factors.15 Moreover, it was paid much attention that arteries displayed elevated expression of senescence markers instigated by uremic milieu in CKD patients could account for early vascular aging and vascular dysfunctions of microvasculature which ultimately lead to increased cardiovascular complication.16 It is known that the incidence of CVD in Asian countries, including Japan, was historically far lower than that in Western countries, although there is a problem of mortality and morbidity from stroke.17 Moreover, an increase in the number of patients with heart failure is an international health-related problem from the point of view of a social/economic burden. In particular, the number of older patients has increased with the rapid aging of society in Japan, and the prevention of heart failure following CVD is a significant issue.18 We focused that PWV is pressure-dependent, CAVI less so, and ASI may capture arterial wall mechanics under reperfusion after occlusion. This could explain its unique association with a history of CVDs in CKD. This study aimed to evaluate the existence and progression of atherosclerosis and measure ASI in patients with CKD with atherosclerosis. The recent decline in CVD in Western countries has been attributed to improvements in traditional risk factors such as lowering low-density lipoprotein cholesterol, controlling blood pressure, and quitting smoking, among others.4,5 Meanwhile, in Japan, the lower CVD incidence was considered in part to be the result of the traditional Japanese lifestyle, including a low-calorie and low-fat diet, unlike that in Western countries; however, CVD increased after the prevalence of the Western diet until 1970 and declined slowly.17 In this study, as more than 70% of the study participants received cholesterol-lowering drugs, no significant difference was observed in cholesterol levels between the high and low-ASI groups. As ASI was higher in patients with hypertension and smokers, it is supposed that ASI may be improved by early smoking cessation instructions and stricter blood pressure control. It has been established that immune cells dominate early atherosclerotic lesions, and inflammation plays a key role in atherosclerotic CVD.19 This study could not reach a statistically significant difference in the inflammatory markers between the low- and high-ASI groups, possibly due to the small number of enrollments. Recently, much attention has been paid to lifestyle modifications,15 but no statistically significant difference in exercise habits was found. A recent meta-analysis in Japan demonstrated that brachial-ankle PWV is a useful marker for predicting future cardiovascular events in Japanese participants without a previous history of CVD, independent of the conventional model used for risk assessment.20,21 We hypothesized that ASI using our device may also be able to assess a certain vascular damage to cause CVD in addition to just stiffness because an alteration in arterial vessels detected by PWV may be similar to that observed in our ASI. In this pilot study, we demonstrated that ASI significantly correlates with PWV, but that only ASI, not PWV, associates with CVD history. When we calculated the association between a history of CVD and ASI adjusted with the same covariates used in Table 3, we failed to find any significant association between a history of CVD and ASI. That meant that significant correlation of ASI with PWV was independent of renal function. on the other hand, the association between a history of CVD and ASI was influenced by renal function. The difference may be caused that we recruited the study subjects who were going to our nephrology outpatient-clinic. Most patient were susceptible to hypo-osmolar heart failure with hypoalbuminemia due to amounts of proteinuria, and their CVD events may include more non-arteriosclerosis-related CVDs. Thus, we speculated that ASI has a potential to reflects not only the sheer stiffness of the blood vessels, but also the added stress on the blood vessel walls due to volume overload. This study had some limitations. First, a device was developed to draw curves between the volume and pressure of the blood vessel in the measurement area under the cuff, and the elasticity of the blood vessel wall was estimated from this curve. Because the upper arm of a human consists of not only arterial vessels but also muscles, skin, subcutaneous fat, and other tissues, and the arterial vessels in the arm are not anchored, the measurement range may shift while being squeezed by the cuff, resulting in errors, particularly in older people with loose muscles. Nevertheless, other tissues in the arm seem to be uninfluential in ASI because they are all incompressible from the point of view of the biomechanics. Second, vascular tone is easily changed by various stresses such as medications, the ingestion of caffeine and alcohol, and others. Especially, nearly all patients were taking a variety of medications, but these were not considered in multivariate models. Also, it might have been necessary to use standardized values calculated from repeated measurements to evaluate the ability of our device to consider within-individual fluctuations. As to the association between ASI and a history of CVDs, high-ASI patients had significantly worse renal function in the first place. Since CKD itself is a strong determinant of vascular stiffness and CVD, we could not eradicate the possibility that ASI reflects the severity of renal function rather than just arterial stiffness through this study. Finally, the study population was so relatively small because this is a reasonable pilot size. We should emphasize the prognostic value of vascular diseases warrants further evaluation as statistical power is limited and confidence intervals are wide. At last, we simultaneously tested multiple arterial stiffness indices against CVD history without adjustment for multiple comparisons and all models were analyzed with a significance level of 0.05. Thus, the possibility of false positives was still remained. The strengths of this study are as follows: this is the first report of the direct measurement of the vascular pressure–volume curve in the human arm using a new device under development. This device should be refined to meet daily use requirements, such as an automatic home blood pressure monitor, namely simple and user-friendly. Next, feasibility demonstrated in a CKD cohort and ASI uniquely associated with CVD history. Third, we presented clear methodology with structured tables and informative figures. This device can also be used to measure the vascular dilatation rate, which is equivalent to FMD. In this study, owing to the constraints of the experimental protocol, only ASI was examined; however, it is expected that the simultaneous measurement of the vascular dilatation rate will allow for a more comprehensive evaluation of the pathological condition. In conclusion, ASI, measured by a non-invasive device that we have been developing, served as a reliable value to assess atherosclerosis and was the only index to identify actual atherosclerotic disease events in patients with CKD. Although further improvements are needed, this pilot study demonstrates the capability of our device to act as a new atherosclerotic marker. CONFLICTS OF INTEREST HM is the representative of LaView Co, Ltd. The device in this research applied the technology that TM and HM had already patented. The LaView Co, Ltd. had no role in conduct of the study, and the device operation, data collection, and analysis were performed independently by the members of Nagoya University. Other authors had no conflicts of interest to declare. ACKNOWLEDGMENT We would like to thank Editage (www.editage.jp) for editing the English language of this manuscript.